Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jul 11;2(3):E10.
doi: 10.1208/pt020310.

Long-term release of clodronate from biodegradable microspheres

Affiliations

Long-term release of clodronate from biodegradable microspheres

P Perugini et al. AAPS PharmSciTech. .

Abstract

This paper describes the formulation of a biodegradable microparticulate drug delivery system containing clodronate, a bisphosphonate intended for the treatment of bone diseases. Microspheres were prepared with several poly(D,L-lactide-co-glycolide) (PLGA) copolymers of various molecular weights and molar compositions and 1 poly(D,L-lactide) (PDLLA) homopolymer by a water-in-oil-in-water (w/o/w) double emulsion solvent evaporation procedure. Critical process parameters and formulation variables (ie, addition of stabilizing agents) were evaluated for their effect on drug encapsulation efficiency and clodronate release rate from microparticles. Well-formed clodronate-loaded microspheres were obtained for all polymers by selecting suitable process parameters (inner water/oil volume ratio 1:16, temperature-raising rate in the solvent evaporation step 1 degree C/min, 2% wt/vol NaCl in the external aqueous phase). Good yields were obtained in all batches of clodronate microspheres (above 60%); drug encapsulation efficiencies ranged between 49% and 75% depending on the polymer used. Clodronate release from all copolymer microspheres was completed in about 48 hours, while those from PDLLA microspheres required about 20 days. The change of microsphere composition by adding a surfactant such as Span 20 or a viscosing agent such as carboxymethylcellulose extended the long-term release up to 3 months. Clodronate was successfully entrapped in PLGA and PDLLA microspheres, and drug release could be modulated from 48 hours up to 3 months by suitable selection of polymer, composition, additives, and manufacturing conditions.

PubMed Disclaimer

References

    1. Delmas PD, Meunier PJ. The management of Paget's disease of bone. New Engl J Med. 1997;336:558–566. doi: 10.1056/NEJM199702203360807. - DOI - PubMed
    1. Kanis JA. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol. 1996;35(Suppl 5):61–67. doi: 10.3109/02841869609083972. - DOI - PubMed
    1. Fleisch H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55–62. doi: 10.3109/07853899708998743. - DOI - PubMed
    1. Shinoda H, Adamek G, Felix R, Fleish H, Schenk R. Structure-activity relationship of various bisphosphonates. Cale Tissue Int. 1983;35:87–99. doi: 10.1007/BF02405012. - DOI - PubMed
    1. Yakatan GJ, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther. 1982;31:402–410. doi: 10.1038/clpt.1982.51. - DOI - PubMed

Publication types

LinkOut - more resources